

# Randomised placebo controlled trial of outpatient cervical ripening with isosorbide mononitrate (IMN) prior to induction of labour - clinical trial with analyses of efficacy, cost effectiveness and acceptability

|                                        |                                                       |                                                      |
|----------------------------------------|-------------------------------------------------------|------------------------------------------------------|
| <b>Submission date</b><br>13/06/2005   | <b>Recruitment status</b><br>No longer recruiting     | <input type="checkbox"/> Prospectively registered    |
|                                        |                                                       | <input type="checkbox"/> Protocol                    |
| <b>Registration date</b><br>25/07/2005 | <b>Overall study status</b><br>Completed              | <input type="checkbox"/> Statistical analysis plan   |
|                                        |                                                       | <input checked="" type="checkbox"/> Results          |
| <b>Last Edited</b><br>16/03/2020       | <b>Condition category</b><br>Pregnancy and Childbirth | <input type="checkbox"/> Individual participant data |

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Jane Norman

**Contact details**  
University of Glasgow Division of Developmental Medicine  
3rd Floor, Queen Elizabeth Building  
Glasgow Royal Infirmary  
10 Alexandra Parade  
Glasgow  
United Kingdom  
G31 2ER  
+44 (0)141 211 4708  
[j.e.norman@clinmed.gla.ac.uk](mailto:j.e.norman@clinmed.gla.ac.uk)

## Additional identifiers

**Protocol serial number**  
RN04OB007

# Study information

## Scientific Title

Randomised placebo controlled trial of outpatient cervical ripening with isosorbide mononitrate (IMN) prior to induction of labour - clinical trial with analyses of efficacy, cost effectiveness and acceptability

## Acronym

IMOP

## Study objectives

Outpatient isosorbide mononitrate will result in a shorter inpatient stay before delivery, decreased costs to the health service, and greater maternal satisfaction with induction of labour, compared with placebo treatment

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Primary study design

Interventional

## Study design

Randomised controlled trial

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Cervical ripening prior to induction of labour

## Interventions

Isosorbide mononitrate 40 mg (or placebo) given vaginally 48 hours, 32 hours and 16 hours prior to scheduled admission for induction of labour.

## Intervention Type

Drug

## Phase

Not Specified

## Drug/device/biological/vaccine name(s)

Isosorbide mononitrate (IMN)

## Primary outcome(s)

i. Elapsed time interval from hospital admission to vaginal delivery (defined as the time from admission for inpatient induction or admission in labour to delivery)

- ii. Costs to the health service of induction of labour
- iii. Womens experience of induction of labour

**Key secondary outcome(s)**

- iv. Operative delivery rates
- v. Incidence of unscheduled admission for reasons other than labour commencing
- vi. Duration and frequency of neonatal admissions to special care
- vii. Incidence of adverse maternal and fetal outcomes such as uterine hypercontractility, postpartum haemorrhage (maternal outcomes) and meconium stained liquor, five minute Apgar of less than seven (fetal outcomes)
- viii. Length of labour
- ix. Oxytocin augmentation rates
- x. Epidural usage
- xi. Proportion with unfavourable cervix at 24 hours after admission
- xii. Requirement for additional inpatient cervical ripening agent

**Completion date**

31/01/2007

**Eligibility****Key inclusion criteria**

- 1. Bishop score less than or equal to 6
- 2. Singleton pregnancy
- 3. Nulliparity
- 4. Gestation greater than or equal to 37 completed weeks
- 5. Willing to self administer vaginal tablets

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

Female

**Key exclusion criteria**

Fetal compromise of sufficient severity such that daily fetal monitoring is scheduled

**Date of first enrolment**

01/02/2005

**Date of final enrolment**

31/01/2007

**Locations**

## Countries of recruitment

United Kingdom

Scotland

## Study participating centre

University of Glasgow Division of Developmental Medicine

Glasgow

United Kingdom

G31 2ER

## Sponsor information

### Organisation

Greater Glasgow Health Board (North Glasgow University Hospitals Division) and The University of Glasgow (UK)

### ROR

<https://ror.org/05kdz4d87>

## Funder(s)

### Funder type

Charity

### Funder Name

Wellbeing (Charity) Ref. CT 2004

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

| Output type                     | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| <a href="#">Results article</a> | results | 25/07/2006   |            | Yes            | No              |

|                                               |                               |            |            |     |     |
|-----------------------------------------------|-------------------------------|------------|------------|-----|-----|
| <a href="#">Results article</a>               | results                       | 01/08/2009 |            | Yes | No  |
| <a href="#">Participant information sheet</a> | Participant information sheet | 11/11/2025 | 11/11/2025 | No  | Yes |
| <a href="#">Study website</a>                 | Study website                 | 11/11/2025 | 11/11/2025 | No  | Yes |